Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe? Abstract #238

Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).
Aim(s): To determine if PRRNT can be performed in patients (pts) with only one kidney or non-functional kidney(s) and progressive, life-threatening NET.
Materials and methods: Twenty-five patients (mean age 57 yr±13) with metastasized NET and having a single kidney (n=19), functional single kidney (n=4), or on dialysis (n=2) were treated with Y-90 (n=2) , Lu-177 (n=21) DOTATATE and combination of Lu-177 and Y-90 (n=2) under renal protection using amino acids (lysine+arginine) and in addition a gelatine agent (Gelofusal).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad

To read results and conclusion, please login ...

Further abstracts you may be interested in

#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#236 Very Long-term Follow-up (> 5 years) of Renal Function of Neuroendocrine Tumor Patients Treated with Five or More Cycles of Peptide Receptor Radionuclide Therapy (PRRNT)
Introduction: Nephrotoxicity is one of the primary concerns in neuroendocrine tumor (NET) patients (pts.) treated with peptide receptor radionuclide therapy (PRRNT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#567 Efficacy of Combined Peptide Receptor Radionuclide Therapy and Radiofrequency Ablation for the Management of Hepatic Metastases of Neuroendocrine Tumors
Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum
#571 Safety and Efficacy of Peptide Receptor Radionuclide Therapy after Liver Transplantation in Metastatic Neuroendocrine Tumors
Introduction: Liver transplantation is an important option for patients of neuroendocrine tumors (NET) with metastases limited to the liver. Peptide receptor radionuclide therapy (PRRNT) is effective in the management of metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Richard P Baum